Publication | Open Access

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic VariantsAdjuvant OlaparibBreast CancerCancer TreatmentOncologyRadiation Oncology